Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice (mim-tRNA)

ABSTRACT: In this study, we utilized a mouse model of mucopolysaccharidosis type I (MPS-I) carrying a homozygous nonsense mutation in the Idua gene (Idua-W401X, TGG→TAG) to develop rAAV-delivered sup-tRNA therapeutics that can overcome a pathogenic UAG premature termination codon (PTC).

ORGANISM(S): Mus musculus

PROVIDER: GSE179272 | GEO | 2021/11/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice (amplicon)

Project description:In this study, we utilized a mouse model of mucopolysaccharidosis type I (MPS-I) carrying a homozygous nonsense mutation in the Idua gene (Idua-W401X, TGG→TAG) to develop rAAV-delivered sup-tRNA therapeutics that can overcome a pathogenic UAG premature termination codon (PTC).

2021-11-30 | GSE179270 | GEO

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice (tRNA_charging)

2021-11-30 | GSE189145 | GEO

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice (mRNA-seq)

2021-11-30 | GSE189146 | GEO

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice (ribosome profiling)

2021-11-30 | GSE179274 | GEO

Establishment of patient-derived bone organoids to recapitulate and dissect Hurler syndrome's skeletal disease

Project description:Mucopolysaccharidosis type I is a disease caused by the mutation of the IDUA gene, encoding the alpha-L-Iduronidase enzyme. Accumulation of glycosamminoglycans (GAGs) due to IDUA deficiency results in a complex skeletal phenotype referred to as dysostosis multiplex. The cellular and molecular pathogenetic mechanisms underlying dysostosis multiplex are still poorly understood. In this study we adopted in vitro and in vivo experimental systems based on patient derived bone marrow stromal cells (BMSC) to generate chondroid and bone rudiments. Transcriptome analysis of chondroid pellet at 5 weeks generated in vitro with BMSCs derived from HD and MPS IH could help to elucidate molecular mechanisms underlying the skeletal phenotype of Hurler Syndrome.

2024-06-24 | E-MTAB-13129 | biostudies-arrayexpress

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice.

Project description:Gene therapy is a potentially curative medicine for many currently untreatable diseases, and recombinant adeno-associated virus (rAAV) is the most successful gene delivery vehicle for in vivo applications1-3. However, rAAV-based gene therapy suffers from several limitations, such as constrained DNA cargo size and toxicities caused by non-physiological expression of a transgene4-6. Here we show that rAAV delivery of a suppressor tRNA (rAAV.sup-tRNA) safely and efficiently rescued a genetic disease in a mouse model carrying a nonsense mutation, and effects lasted for more than 6 months after a single treatment. Mechanistically, this was achieved through a synergistic effect of premature stop codon readthrough and inhibition of nonsense-mediated mRNA decay. rAAV.sup-tRNA had a limited effect on global readthrough at normal stop codons and did not perturb endogenous tRNA homeostasis, as determined by ribosome profiling and tRNA sequencing, respectively. By optimizing the AAV capsid and the route of administration, therapeutic efficacy in various target tissues was achieved, including liver, heart, skeletal muscle and brain. This study demonstrates the feasibility of developing a toolbox of AAV-delivered nonsense suppressor tRNAs operating on premature termination codons (AAV-NoSTOP) to rescue pathogenic nonsense mutations and restore gene function under endogenous regulation. As nonsense mutations account for 11% of pathogenic mutations, AAV-NoSTOP can benefit a large number of patients. AAV-NoSTOP obviates the need to deliver a full-length protein-coding gene that may exceed the rAAV packaging limit, elicit adverse immune responses or cause transgene-related toxicities. It therefore represents a valuable addition to gene therapeutics.

| S-EPMC9446716 | biostudies-literature

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-11-30 | GSE179275 | GEO

Engineered tRNAs suppress nonsense mutations in cells and in vivo

Project description:we introduce a strategy to repurpose sense-codon decoding tRNA into efficient suppressors of the three nonsense mutation-induced PTCs (UGA, UAG and UAA). The suppressor tRNAs restore function of a model and disease-related protein

2023-04-04 | GSE191048 | GEO